Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial
Key Points
Key points are not available for this paper at this time.
Abstract
Valneva, Coalition for Epidemic Preparedness Innovation, and EU Horizon 2020.
AI에게 질문
Like
Bookmark
Share
View Full Paper
AI에게 질문
Like
Bookmark
Share
View Full Paper
Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial | Synapse